This section of pediculosis.com is devoted to news about corporate developments and company announcements. |
Tyratech have announced increased sales for the Vamousse head lice treatment, and are extending their distribution network in both the US and the UK.
Two companies producing market-leading head lice products have released recent trading updates.
TyraTech has announced deals with further suppliers in the UK for their VaMousse head lice treatment.
Tyratech, inc last week announced a successful share offering along with deals for distribution of its head lice products with UK chemist chains.
TyraTech Inc recently announced that their VaMOUSSE! range of head lice products are available to purchase online in the United States.
Tyratech Inc. is in discussions with distributors to increase the exposure of its head lice treatment range to markets in the US.
Eden Research has announced an agreement with Neo-Pharma Innovations to develop their terpene-based head lice treatment for commercial sale.
Hatchtech, Pty Ltd have announced the completion of their financing round and published new data on the active ingredient in their DeOvo pediculicide product.
TyraTech, Inc, has received notification from the UK regualtory body that their VaMOUSSE!™ head lice product has been registered as a medical device.
The active ingredient in the DeOvo head lice treatment, produced by Hatchtech Pty Ltd, has been granted a patent by the US Patent and Trademark Office.